Company overview
Basic information
Company name
Kysil trans auto, UAB
Company code
306879704
VAT code
LT100017447714
Registered address
Kauno r. sav., Alšėnų sen., Narsiečių k., Antano Sereikos g. 26-1, LT-53304
Registration date
2024-06-26
Company age: 2 y. 4 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Website
None
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Private Limited Liability Company
NACE activity
Freight transport by road
Ownership form
Privately owned with foreign capital
UAB Kysil trans auto
Company code: 306879704
Address: Kauno r. sav., Alšėnų sen., Narsiečių k., Antano Sereikos g. 26-1, LT-53304
VAT code: LT100017447714
Description
This description was generated by artificial intelligence.
Kysil trans auto, UAB (company code 306879704) is an operational private limited liability company registered in 2024. It belongs to the sector of national private non-financial companies and is classified as privately owned, with Lithuanian natural and legal persons holding more than 50% of the authorised capital and capital from foreign investors also included. Governance is CEO only. The company is a micro-sized business and its registered address is in Narsieciu k., Alšenu sen., Kauno r. sav., Kauno apskr. Its main activity is EVRK H.49.41.00, Freight transport by road. The share capital amounts to EUR 9.0K. In 2025, the company generated EUR 68.7K in revenue and EUR 2.7K in net profit, corresponding to a 3.9% profit margin. At year-end, equity stood at EUR 11.8K, total assets at EUR 57.4K and liabilities at EUR 45.7K. The workforce averaged 3 employees in 2025 and remained at 3 so far in 2026, while the average monthly wage increased from EUR 725.78 in 2025 to EUR 849.47 so far in 2026.
Download a detailed company report
Make confident decisions with all the information about Kysil trans auto, UAB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.